Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks
Timothy Craig, Bruce Zuraw, Hilary Longhurst, Marco Cicardi, Konrad Bork, Clive Grattan, Constance Katelaris, Gordon Sussman, Paul K Keith, William Yang, Jacques Hébert, Jana Hanzlikova, Petra Staubach-Renz, Inmaculada Martinez-Saguer, Markus Magerl, Emel Aygören-Pürsün, Henriette Farkas, Avner Reshef, Shmuel Kivity, Sergio Neri, Ioana Crisan, Teresa Caballero, Maria L Baeza, Maria Dolores Hernandez, Henry Li, William Lumry, Jonathan A Bernstein, Iftikar Hussain, John Anderson, Lawrence B Schwartz, Joshua Jacobs, Michael Manning, Donald Levy, Marc Riedl, Sandra Christiansen, Henrike Feuersenger, Ingo Pragst, Sarah Mycroft, Dipti Pawaskar, Iris Jacobs, COMPACT Investigators, Timothy Craig, Bruce Zuraw, Hilary Longhurst, Marco Cicardi, Konrad Bork, Clive Grattan, Constance Katelaris, Gordon Sussman, Paul K Keith, William Yang, Jacques Hébert, Jana Hanzlikova, Petra Staubach-Renz, Inmaculada Martinez-Saguer, Markus Magerl, Emel Aygören-Pürsün, Henriette Farkas, Avner Reshef, Shmuel Kivity, Sergio Neri, Ioana Crisan, Teresa Caballero, Maria L Baeza, Maria Dolores Hernandez, Henry Li, William Lumry, Jonathan A Bernstein, Iftikar Hussain, John Anderson, Lawrence B Schwartz, Joshua Jacobs, Michael Manning, Donald Levy, Marc Riedl, Sandra Christiansen, Henrike Feuersenger, Ingo Pragst, Sarah Mycroft, Dipti Pawaskar, Iris Jacobs, COMPACT Investigators
Abstract
Background: For the prevention of attacks of hereditary angioedema (HAE), the efficacy and safety of subcutaneous human C1-esterase inhibitor (C1-INH[SC]; HAEGARDA, CSL Behring) was established in the 16-week Clinical Study for Optimal Management of Preventing Angioedema with Low-Volume Subcutaneous C1-Inhibitor Replacement Therapy (COMPACT).
Objective: To assess the long-term safety, occurrence of angioedema attacks, and use of rescue medication with C1-INH(SC).
Methods: Open-label, randomized, parallel-arm extension of COMPACT across 11 countries. Patients with frequent angioedema attacks, either study treatment-naive or who had completed COMPACT, were randomly assigned (1:1) to 40 IU/kg or 60 IU/kg C1-INH(SC) twice per week, with conditional uptitration to optimize prophylaxis (ClinicalTrials.gov registration no. NCT02316353).
Results: A total of 126 patients with a monthly attack rate of 4.3 in 3 months before entry in COMPACT were enrolled and treated for a mean of 1.5 years; 44 patients (34.9%) had more than 2 years of exposure. Mean steady-state C1-INH functional activity increased to 66.6% with 60 IU/kg. Incidence of adverse events was low and similar in both dose groups (11.3 and 8.5 events per patient-year for 40 IU/kg and 60 IU/kg, respectively). For 40 IU/kg and 60 IU/kg, median annualized attack rates were 1.3 and 1.0, respectively, and median rescue medication use was 0.2 and 0.0 times per year, respectively. Of 23 patients receiving 60 IU/kg for more than 2 years, 19 (83%) were attack-free during months 25 to 30 of treatment.
Conclusions: In patients with frequent HAE attacks, long-term replacement therapy with C1-INH(SC) is safe and exhibits a substantial and sustained prophylactic effect, with the vast majority of patients becoming free from debilitating disease symptoms.
Keywords: C1-esterase inhibitor; HAEGARDA; Hereditary angioedema; Long-term; Prophylaxis; Safety; Subcutaneous.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed